Unlocking the next generation of complement therapies We are focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain and eye. Our science We target C1q to block all damaging components of the immune system’s classical complement pathway. Learn more Our pipeline […]